William Shappley, MD
Urology · Germantown, TNNPI 1508889817
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,004 of the $14,994 with a category attached, or 60.0%. 30 manufacturers reported payments, led by Accord Healthcare, Inc. at 40.5% of the total. 2025 is the largest year on record at $7,643, more than ten times the $401 reported in 2019.
Across 269 payments — averaging $55.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Accord Healthcare, Inc.$6K
- Teleflex LLC$1K
- Coloplast$1K
- Sumitomo Pharma America, Inc.$814
- Axonics, Inc.$762
- Procept Biorobotics Corporation$701
- plus $4K from 24 others
What the payments were for
- Consulting fees$9757%
- Speaking & faculty fees$4,22528%
- Travel & lodging$6825%
- Food & beverage$9,00460%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Accord Healthcare, Inc. | 10 | $6,075 |
| Teleflex LLC | 16 | $1,463 |
| Coloplast | 63 | $1,433 |
| Sumitomo Pharma America, Inc. | 26 | $814 |
| Axonics, Inc. | 28 | $762 |
| Procept Biorobotics Corporation | 10 | $701 |
| Medtronic(2 entities) | 9 | $550 |
| Boston Scientific | 7 | $453 |
| Urogen Pharma, Inc. | 11 | $404 |
| C. R. Bard, Inc. & Subsidiaries | 11 | $283 |
| AbbVie(2 entities) | 11 | $241 |
| Endo Pharmaceuticals Inc. | 3 | $239 |
| Astellas Pharma US Inc | 13 | $214 |
| Angiodynamics, Inc. | 1 | $150 |
| Myovant Sciences Inc. | 8 | $146 |
| Myriad Genetic Laboratories, Inc. | 8 | $139 |
| Merck | 6 | $136 |
| AstraZeneca | 1 | $112 |
| Pfizer | 6 | $104 |
| Rochester Medical Corporation | 3 | $102 |
| Olympus America Inc. | 2 | $100 |
| Johnson & Johnson | 4 | $87 |
| Endo USA, Inc. | 3 | $56 |
| Biotissue Holdings Inc. | 1 | $49 |
| Tempus AI, Inc | 2 | $49 |
| Novartis | 2 | $40 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Smith+Nephew | 1 | $24 |
| Davol Inc. | 1 | $24 |
| Axogen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,994 in reported general payments places this provider in the 80th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 108 | $88,734 |
| MyrbetriqMirabegron | 106 | $84,637 |
| Dutasteride | 566 | $18,535 |
| Tamsulosin Hcl | 958 | $13,012 |
| Solifenacin Succinate | 105 | $9,087 |
| Oxybutynin Chloride | 410 | $6,539 |
| Bethanechol Chloride | 96 | $4,138 |
| Trimethoprim | 62 | $3,404 |
| Testosterone | 29 | $2,527 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 139 | $2,441 |
| Ciprofloxacin Hcl | 383 | $2,254 |
| Silodosin | 24 | $2,193 |
| Finasteride | 133 | $2,068 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,870 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 201 | $1,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $814 | $88,734108 claims |
| Astellas Pharma US IncMyrbetriq | $214 | $84,637106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 276 urology providers in Tennessee.
Other urology in Germantown
- Paul EberGermantown$476K
- Ravi ChauhanGermantown$182K
- Adam StewartGermantown$75K
- Michael GranieriGermantown$71K
- William ShappleyGermantown$17K
- John AdamsGermantown$14K
- Zachary CorrGermantown$13K
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Gautam JayramNashville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.